Abstracts tagged "Disease Activity"

Abstract Number: 2396 • ACR Convergence 2024
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Anna Korogodina¹, Erin Sundel¹, Yaroslav Markov², Vasileios Kyttaris³, Julianne O'Connell¹ and Suzanne Krishfield¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Yale School of Medicine, New Haven, ³BIDMC, Boston, MA
Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
Abstract Number: 0232 • ACR Convergence 2024
Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study
Seyyid Bilal Acikgoz¹, Ricardo Sabido-Sauri², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel², Sylvia Sangwa⁴, Elliot Hepworth² and Sibel Aydin⁵, ¹University of Ottawa, Rheumatology, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…
Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Alexandre Matar¹, Maya Breitman², Tracey Bonfield³, Maricela Haghiac⁴, Jane Reese³, Emma Barnboym⁵, Steven Lewis⁶, Hillard Lazarus⁷ and Nora Singer⁸, ¹MetroHealth, Westlake, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Metrohealth Medical Center, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶Case Western University, MetroHealth, Cleveland, OH, ⁷Case Western Reserve University/University Hospitals, Cleveland, OH, ⁸MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
Abstract Number: 0623 • ACR Convergence 2024
Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge⁴, Stan Kamp³, Nancy Redinger³, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yanfeng Li⁵, hu Zeng⁵, Uma Thanarajasingam⁵, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester
Background/Purpose: We have recently validated a plasma Lupus Flare Risk Index (L-FRI; Munroe et al. Ann Rheum Dis. 2024. 83 [Supp 1]: 402) and Lupus…
Abstract Number: 0850 • ACR Convergence 2024
Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis
Komal Verma Saluja¹, Harshvardhan Khokhar², Amit Sharma³ and Saurabh Chittora², ¹Government Medical college Kota, Kota, Rajasthan, India, ²Government Medical college Kota, Kota, India, ³Fortis hospital Jaipur, Jaipur, India
Background/Purpose: Conventional Disease Activity Score 28 has variable sensitivity, subjectivity, inherent bias due to certain variables such as more weightage to joint tenderness and overestimation…
Abstract Number: 1317 • ACR Convergence 2024
Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis
Yasmine LAMROUS, Camille LEGLISE, Audrey VANRENTERGHEM, Taieb CHOUAKI and Djamal-Dine DJEDDI, CHU AMIENS PICARDIE, AMIENS, France
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses the most common chronic rheumatologic manifestations in children. It results from the interplay of genetic, environmental, and infectious factors.…
Abstract Number: 1369 • ACR Convergence 2024
Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Peter Youssef¹, Sabina Ciciriello², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Nicole Walsh⁶, Miriam Calao⁶ and Geoffrey Littlejohn⁷, ¹Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ²The University of Melbourne, Melbourne, Victoria, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To describe the real-world treatment patterns, response and persistence in rheumatoid arthritis (RA) patients (pts) treated with upadacitinib (UPA).Methods: This retrospective, non-interventional, multicenter cohort…
Abstract Number: 1593 • ACR Convergence 2024
Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis
Federica Pallotti¹, Philippe Bonniaud², Perrine SMETS³, stephanie Habib⁴, Amandine Perier⁵, Alban Deroux⁶, Julie Mankikian⁷, Antoine Neel⁸, Clémentine Rousselin⁹, Raphaele Seror¹⁰, Camille Taille¹¹, Etienne Crickx¹², Candice La Croix¹³, Philippe Blanche¹⁴, Loïc Guillevin¹⁵, Xavier Puéchal¹⁶ and Benjamin Terrier¹⁷, and French Vasculitis Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ³Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁴Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁵CH de Niort, Niort, France, ⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁷CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, ⁸Department of Internal Medicine, CHU Nantes, Nantes, France, ⁹Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, ¹⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹¹Bichat Hospital, Paris, France, ¹²Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, ¹³Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, ¹⁴Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, ¹⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
Abstract Number: 1912 • ACR Convergence 2024
Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Cassie Clinton⁵, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: There is regional variation in the clinical characteristics, treatment, and outcomes of patients with inflammatory arthritis in the US. Despite a higher reported prevalence of…
Abstract Number: 2252 • ACR Convergence 2024
Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
Maya H. Buch¹, Patrick Verschueren², Roberto Caporali³, Thomas Huizinga⁴, Edmund V. Ekoka Omoruyi⁵, Dick de Vries⁶, Jeffrey Ritsema⁷, Francesco De Leonardis⁸ and Daniel Aletaha⁹, ¹Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁵Biostatistics, Galapagos NV, Mechelen, Belgium, ⁶Clinical Development, Galapagos BV, Leiden, Netherlands, ⁷Medical Affairs, Galapagos BV, Leiden, Netherlands, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor for the treatment of moderate to severe RA. FINCH 4 (NCT03025308) is an ongoing, open-label,…
Abstract Number: 2415 • ACR Convergence 2024
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Nehad Soloman¹, Jawad Bilal², Romy Cabacungan³, Scott Milligan⁴, Andrew Sharobeem⁵, John Tesser⁶ and Henry Leher⁷, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²University of Arizona, Tucson, AZ, ³Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, ⁴Trio Health, Louisville, CO, ⁵AARA, Peoria, AZ, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Aurinia Pharma, Stowe, VT
Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0545 • ACR Convergence 2024
Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Stylianos Georgiadis¹, Marion Pons², Simon Horskjær Rasmussen², Merete Hetland³, Louise Linde², Daniela DiGuiseppe⁴, Brigitte Michelsen⁵, Johan Karlsson Wallman⁶, Tor Olofsson⁷, Karel Pavelka⁸, Jakub Závada⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Catalin Codreanu¹¹, Daniel Melim¹², Diogo Esperança Almeida¹³, Tore K. Kvien¹⁴, Vappu Rantalaiho¹⁵, Ritva Peltomaa¹⁶, Bjorn Gudbjornsson¹⁷, Olafur Palsson¹⁸, Ovidiu Rotariu¹⁹, Ross MacDonald¹⁹, Ziga Rotar²⁰, Katja Perdan-Pikmajer²⁰, Karin Laas²¹, Florenzo Iannone²², Adrian Ciurea²³, Mikkel Ostergaard²⁴ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁴Karolinska Institutet, Stockholm, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁸Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹University of Medicine and Pharmacy, Bucharest, Romania, ¹²Hospital Egas Moniz, Lisbon, Portugal, ¹³Hospital de Braga, Braga, Portugal, ¹⁴Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁵Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ¹⁶Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ¹⁷Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁸University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁹University of Aberdeen, Aberdeen, United Kingdom, ²⁰University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ²¹East-Tallinn Central Hospital, Tallinn, Estonia, ²²Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²³University Hospital Zurich, Zürich, Switzerland, ²⁴Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In observational studies, several longitudinal methods have been proposed to impute missing data of an individual by using the available information of the same…
Abstract Number: 0626 • ACR Convergence 2024
Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Samira García-Hirsh⁶, José Alfaro-Lozano⁶, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Physician-reported disease activity has a modest association with patient-reported outcomes (PROs) in systemic lupus erythematosus patients. The aim of this study is to evaluate…
Abstract Number: 0867 • ACR Convergence 2024
Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis
Marc Blanchard¹, Cinja Koller², Jules Maglione³, Patrick Hermann¹ and Thomas Hügle³, ¹Lausanne University Hospital, Lausanne, Vaud, Switzerland, ²Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) care faces challenges due to a shortage of healthcare providers, an increasing patient population and the remote locations of many patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].